Unlearn vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital twin platform (TwinRCT) replacing placebo arms in clinical trials. $100M+ raised ($50M rounds x2); EMA-qualified PROCOVA for Phase 2/3; FDA positive feedback.
About
Unlearn is an AI company that develops machine learning-generated digital twins of clinical trial participants, enabling pharmaceutical companies to run smaller, faster, and more statistically powerful trials. Its TwinRCT solution uses PROCOVA — a covariate adjustment methodology now officially qualified by the European Medicines Agency for use in Phase 2 and 3 trials with continuous outcomes — to augment or replace traditional placebo control arms with AI-generated synthetic patient profiles. The FDA has provided positive feedback supporting PROCOVA''s use in covariate-adjusted analyses across clinical development. Unlearn has built its strongest traction in neuroscience — Alzheimer''s disease and ALS — where small patient populations and high mortality rates make trial efficiency critical. The company has raised approximately $100M across two $50M funding rounds, with the most recent round in 2024.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.